



Genetic Signatures

Transforming Molecular Diagnostics

FY2026 Financial Results and Market Update

25 August 2026

ersonal use only






Contents

- About Genetic Signatures
- FY2026 Highlights
- FY2026 Financial Results
- FY2026 Key Achievements
- Growth Strategy Progress
- Outlook

ersonal use only






Specialists in syndromic detection of infectious diseases

- Genetic Signatures is an ASX listed molecular diagnostics company, delivering innovative pathogen detection underpinned by patented 3base[®] technology and *EasyScreen*[™] assays
- Our respiratory and enteric multiplex PCR solutions screen up to 24 pathogens in a single, automated test, streamlining workflows and accelerating results for diagnostic laboratories, and supporting infection control decisions and appropriate patient management

Manufactured in Australia, accessible across the globe

- Genetic Signatures' *EasyScreen*[™] products are accessible in over 30 countries
- Our team have direct representation in the United States and United Kingdom
- We have distribution partners in Africa, and across Europe
- Products CE-IVD, FDA, TGA, or as RUO solutions



Key benefits of syndromic molecular detection



Improved sensitivity, specificity & reliability

Compared to traditional diagnostic methods



Supports antimicrobial stewardship

Targeted, appropriate treatment reduces unnecessary and ineffective antibiotic use



Increased pathogen coverage

Multiplex testing for the most clinically relevant pathogens in a single test



Reduced patient burden

Single sample required compared to multiple samples for microscopic testing



Reduced labour & stress

One sample – one workflow. Many automated steps reducing labour costs, handling, turnaround, training & errors




Improved efficiencies

Reduction in time to results from days to a few hours enabling rapid treatment and improved patient outcomes



- Growth expected across all regions, though strongest across APAC markets
 - Traditional methods still widely used in many countries - opportunity for transition to syndromic testing
- Greater awareness builds for policy and testing algorithm changes, further building demand
- Other key drivers of demand include:
 - Rising global population
 - Prevalence of infectious disease
 - Multiplex testing advances
 - Increased demand for rapid, accurate & comprehensive results
 - Government & institutional investment in health & infection control

Syndromic Multiplex Diagnostic Market CAGR (%), Growth Rate by Region, 2026 - 2031



Source: Mordor Intelligence





- Net loss down 30% to \$14.0 million (FY25: \$20.1 million)
- Net operating cash outflow down 37% to \$7.8 million (FY25: \$12.3 million)
- Cash and term deposits of \$22.1M on 30 June 2026, no debt
- Revenue of \$14.8 million, down 7% on the prior year (FY25: \$15.9 million), amid a competitive, price-sensitive market and a delayed Australian respiratory season
- Organisational restructuring completed in April 2026 with expected annual cost savings of \$5 million from FY2027 onwards
- Ten-year supply agreement signed with Hvidovre Hospital, Denmark; first commercial order received and testing commenced in August 2026
- Long term supply agreement signed in Australia with built in annual growth
- New CEO appointed and a comprehensive organisational review completed resulting in the release of the Company's growth strategy



A\$'000	FY2026	FY2025
Sales revenue	14,840	15,900
Cost of materials	(8,499)	(7,128)
Gross profit	6,341	8,772
Other income	4,491	3,853
Interest revenue	985	1,611
Employee benefits expense	(13,424)	(16,066)
Depreciation & amortisation	(2,063)	(2,404)
Impairment expenses	(2,080)	(6,996)
Other expenses	(8,255)	(8,874)
Loss before income tax	(14,006)	(20,104)

- Net loss down 30% to \$14.0 million (FY25: \$20.1 million) with significantly improved operational performance
- Net operating cash outflow down 37% to \$7.8 million (FY25: \$12.3 million)
- Revenue of \$14.8 million (FY2025: \$15.9 million), down 7%
- Employee expenses reduced 16%, reflecting the early results of the FY2026 organisational restructuring
- Cash balance sheet remains strong, with \$22.1 million in cash and term deposits on 30 June 2026 and no debt



Reset organisational and cost structure

- Completed rightsizing of the Company following a line-by-line expenditure review resulting in total annualised cost savings of \$5M from FY2027
- Established purchasing processes and controls that are expected to result in further operational savings
- Established AI policy, began AI-enablement of administrative and certain product development functions within the organisation
- Increased cash runway to allow for the organisation to deliver on key strategic objectives



Secured long term supply agreements

- Signed strategically significant Danish contract with Hvidovre Hospital demonstrating traction in the EMEA market and opening new opportunities in Europe – completed validation and commenced commercial testing in August 2026
- Secured long term supply agreement in Australia for the *EasyScreen*™ gastrointestinal and respiratory detection kits
- Implemented critical product upgrades to remove supply chain risk and improve laboratory workflow



Reset product and instrument strategy

- Completed product and instrumentation strategy to secure supply for existing long-term contracts, as well as potential new EMEA, APAC and Australian customers
- Two new product development programs commenced to focus on regulatory upgrades and broadening pathogen detection allowing access to wider geographies
- Implemented product upgrades addressing supply chain risks and improving workflow
- Paused development of customised automation equipment and commenced sourcing of off-the-shelf robotics to service customers with cutting edge, user friendly solutions

Progress of the Company's Growth Strategy



Strategic Objective	Stabilise	Optimise	Scale
	March 2026 - August 2026	August 2026 - March 2027	March 2027 – March 2028
Implement organisational restructure	✓		
Review product strategy	✓		
Secure Australian business	✓		
Review market access strategy (USA, EMEA, AU)	✓		
Implement financial controls, savings and reporting	✓		
Finalise board-endorsed product and corporate strategy		✓	
Pause customised instrumentation development		✓	
Develop APAC market access strategy		✓	
Build a culture of excellence and improve organisational productivity		Progressing	
Evaluate potential commercial and strategic partnerships		Progressing	Progressing
Potential APAC rollout			Progressing
New product launches to drive revenue			Progressing
Grow direct EMEA and Australian revenue			Progressing
Grow EMEA distributor revenue			Progressing
Develop long term off the shelf instrumentation strategy			Progressing
Re-entry to the US market			Not yet commenced



- 1 Grow revenue on the stabilised business** With solid long term supply agreements the Company is well placed to grow revenue from current and new customer relationships.
- 2 Focus on profitability** Contracts to improve unit economics with margin discipline are a key objective for FY2027 and beyond.
- 3 Outsource product development** Limit product risk by outsourcing non-core research and development activities.
- 4 Continue disciplined capital deployment** Every dollar spent must be justified against its return, expected outcome, time frame and risk; activity-based spending replaced with outcome-based capital allocation.
- 5 Pursue new growth opportunities with clear value proposition** APAC and EMEA represent opportunities for revenue growth through infection prevention and control in hospitals; while Australian revenue is expected to grow through product extensions.
- 6 Continue to focus on partnerships** Manufacturing, product development, distribution and instrumentation partnerships are actively assessed together with synergistic corporate partnerships.



Genetic Signatures

Transforming Molecular Diagnostics

Contact us

P: +61 (0)2 9870 7580

E: info@geneticsignatures.com

Visit us

geneticsignatures.com

Follow us

